Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CLK1 | P49759 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715950 | 0.85 | DYRK1A (1.00) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL1303393 | 0.85 | RAB9A (0.69) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL5019481 | 0.84 | DYRK1A (0.74) | RAB9ADYRK1ANPC1LCKALDH1A1 | |
| SCHEMBL3708649 | 0.84 | RAB9A (0.76) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL15582913 | 0.83 | LCK (0.58) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL18824277 | 0.82 | DYRK1A (0.74) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL22208373 | 0.82 | RAB9A (0.72) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL1302829 | 0.81 | RAB9A (0.64) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL240597 | 0.81 | SMN1; SMN2 (0.72) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 | |
| SCHEMBL179517 | 0.81 | MAP3K5 (0.60) | RAB9ADYRK1ANPC1CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-04-14 | — | — | US | disclosed |
| EP-3908277-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Zhang, Xiaohu (CN) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | RAB9A 2203/4885DYRK1A 4546/4885NPC1 122/4885 |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | RAB9A 1494/4885DYRK1A 745/4885NPC1 1373/4885 |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | TNF, LITAF, PNLIP | RAB9A 2203/4885DYRK1A 4546/4885NPC1 122/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | RAB9A 2991/4885DYRK1A 623/4885NPC1 1321/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | RAB9A 3154/4885DYRK1A 3965/4885NPC1 97/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | RAB9A 981/4885DYRK1A 1072/4885NPC1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.